Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.240
-0.545-9.42%
Volume:10.84M
Turnover:58.24M
Market Cap:8.36B
PE:-16.65
High:5.790
Open:5.745
Low:5.230
Close:5.785
52wk High:10.410
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:3.11
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-52.14%
ROA:-14.44%
PB:5.53
PE(LYR):-16.65
PS:16.80

Loading ...

CStone Pharma-B Launches Global Phase I Trial for Key ADC Candidate CS5007

Stock News
·
Jun 12

CStone says CS5007 Phase I trial wins Australian ethics approval

Reuters
·
Jun 12

CStone says Phase I data show CS2009 trispecific antibody posts 24% ORR in later-line NSCLC

Reuters
·
Jun 11

Insider Transaction: CEO Yang Jianshu Purchases Additional Shares in CStone Pharmaceuticals

Stock News
·
Jun 10

CStone Pharmaceuticals CEO, President of R&D and Executive Director Acquires 1.0% More Stock

Simply Wall St.
·
Jun 07

AKESO's New Drug Achieves Historic Milestone, Yet Market Cap Plummets by Tens of Billions

Deep News
·
Jun 05

Jefferies Maintains Buy Rating on CStone Pharma, Citing Management Confidence and Promising CS2009 Data

Stock News
·
Jun 04

CStone Pharmaceuticals Says CEO, Directors, Senior Management Initiate Joint Share Purchase Plan

Reuters
·
Jun 03

Key Executives and Board Members of CStone Pharmaceuticals to Purchase Additional Company Shares

Stock News
·
Jun 03

CStone Pharmaceuticals - CEO, Directors, and Senior Management Initiate Joint Share Purchase Plan

THOMSON REUTERS
·
Jun 03

CStone Pharmaceuticals - Share Purchases to Total 2 Mln to 5 Mln Shares From June 2026

THOMSON REUTERS
·
Jun 03

Goldman Sachs Issues Post-ASCO Analysis, Reiterates Buy Rating on CStone with HK$9.44 Target

Stock News
·
Jun 02

CStone Pharmaceuticals Sets 23 June 2026 AGM; Seeks Approval for Director Re-election, 20% Issuance Mandate and Equity Awards to CEO

Bulletin Express
·
Jun 01

CStone Pharma to Seek Shareholder Nod for 20% Issue Mandate, 10% Buy-Back Capacity and CEO Equity Awards

Bulletin Express
·
Jun 01

CStone: ASCO 2026 Data Underscore Robust Efficacy and Safety of Trispecific Antibody CS2009; Phase III Global Trial Planned for Year-End

Bulletin Express
·
Jun 01

CStone presents ASCO data for CS2009 PD-1/VEGF/CTLA-4 trispecific antibody in lung, colorectal cancer trials

Reuters
·
Jun 01

A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Pralsetinib’s First Domestic Launch In China

Simply Wall St.
·
May 25

CStone Pharmaceuticals Plans Share Buyback

MT Newswires Live
·
May 13

CStone Announces Plan to Repurchase up to 136.45 Million Shares After ASCO Meeting

Bulletin Express
·
May 13

CSTONE PHARMA-B Announces Plan to Repurchase Up to 136 Million Shares

Stock News
·
May 13